Demonstration data — verify all information before publication. Not medical or investment advice.

Drug Pipeline

Peptide pipeline across development stages.

Investigational and approved peptide therapeutics grouped by development stage and sponsor company.

Demonstration data — verify all information before publication. Not medical or investment advice.

Preclinical

0
  • No entries at this stage in the demo dataset.

Phase 1

0
  • No entries at this stage in the demo dataset.

Phase 2

5

  • MariTide

    GIPR antagonist / GLP-1 agonist peptide-antibody

    Amgen · Obesity

  • Danuglipron

    Oral small-molecule GLP-1 (peptide-adjacent)

    — · Obesity, Type 2 Diabetes

  • VK2735

    Dual GLP-1 / GIP agonist

    Viking Therapeutics · Obesity

  • GSBR-1290

    Oral small-molecule GLP-1

    Structure Therapeutics · Obesity, Type 2 Diabetes

  • Pemvidutide

    GLP-1 / glucagon dual agonist

    Altimmune · Obesity, MASH

Phase 3

3

  • Retatrutide

    GIP / GLP-1 / glucagon triple agonist

    Eli Lilly · Obesity, Type 2 Diabetes

  • Survodutide

    GLP-1 / glucagon dual agonist

    Zealand Pharma · Obesity, MASH

  • Cagrilintide

    Long-acting amylin analog

    Novo Nordisk · Obesity

Filed

0
  • No entries at this stage in the demo dataset.

Approved

2

  • Semaglutide

    GLP-1 receptor agonist

    Novo Nordisk · Type 2 Diabetes, Obesity

  • Tirzepatide

    Dual GIP / GLP-1 receptor agonist

    Eli Lilly · Type 2 Diabetes, Obesity

Sponsor summary

Eli Lilly

LLY · 6 peptide programs

Novo Nordisk

NVO · 8 peptide programs

Amgen

AMGN · 3 peptide programs

Viking Therapeutics

VKTX · 3 peptide programs

Structure Therapeutics

GPCR · 2 peptide programs

Altimmune

ALT · 2 peptide programs

Zealand Pharma

ZEAL · 5 peptide programs

Terns Pharmaceuticals

TERN · 2 peptide programs